Challenges in Treating Chlamydia trachomatis, Including Rectal Infections: Is It Time to Go Back to Doxycycline?

Area of Science:

• Infectious Diseases
• Microbiology
• Pharmacology

Background:

• Chlamydia trachomatis infections are a common sexually transmitted infection.
• Azithromycin (single-dose) and doxycycline (7-day) are primary treatment options.
• Emerging evidence suggests varying efficacy between these agents.

Purpose of the Study:

• To evaluate and compare the efficacy of single-dose azithromycin versus 7-day doxycycline for treating Chlamydia trachomatis.
• To synthesize recent findings on treatment outcomes across different infection sites.

Main Methods:

• Comprehensive literature search of major databases (MEDLINE, EMBASE, PubMed, Cochrane) from 1990 to June 2021.
• Inclusion of English-language studies: randomized controlled trials, systematic reviews, meta-analyses, retrospective analyses, and case reports.
• Focus on microbiological or clinical outcomes in adolescents and adults.

Main Results:

• Systematic reviews indicate high azithromycin efficacy (96-97%) for genital chlamydia, but with increased failure risk (RR=2.45) compared to doxycycline, especially in symptomatic males.
• Lower azithromycin efficacy (74-87%) reported for rectal chlamydia versus doxycycline (92-100%).
• A key RCT showed significantly higher microbiological cure with doxycycline (26% absolute difference, P < 0.001).

Conclusions:

• Growing evidence supports azithromycin treatment failures, particularly for rectal chlamydia, necessitating a review of current treatment guidelines.
• Doxycycline demonstrates sustained high efficacy for both genital and rectal chlamydia.
• Clinical decisions should balance treatment efficacy, dosing convenience, patient compliance, and sexual risk behaviors.